Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
DALLAS/FORT WORTH, Texas, Dec. 07, 2016 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Vipin Garg, Ph.D., president and chief executive officer, will participate in a fireside chat at the upcoming BMO Prescription for Success Healthcare Conference on Wednesday, December 14, 2016 at 9:00 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s XR-ODT technology platform. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®1, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contact: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Stern Investor Relations, Inc. (212) 362-1200 [email protected]
